Trial reportShock (Augusta, Ga.)2026
Pancreatic Stone Protein in Co-Evaluation With QSOFA and News2 for Early Sepsis Detection at the Emergency Department.
Trial report in Shock (Augusta, Ga.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pancreatic Stone Protein as an Early Predictor of Adverse Events in Patients with Infection Presenting to the Emergency Department: A Pilot Study.Journal of personalized medicine · 2026Article
- Point-of-care LPS-induced TNF-α release testing for early sepsis risk stratification in the emergency department.Frontiers in immunology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEarly sepsis identification at the emergency department (ED) triage is essential for timely treatment and improved outcomes. This study evaluated the diagnostic performance of pancreatic stone protein (PSP) in combination with the quick Sequential Organ Failure Assessment (qSOFA) and the National Early Warning Score (NEWS2) for early sepsis detection.
methodsAs part of the PROMPT study-a noninterventional, multicenter trial across six Greek hospitals-blood samples were collected within the first hour of admission in the emergency department. PSP levels were retrospectively assessed using a nanofluidic near-patient immunoassay device (abioSCOPE, Abionic SA, Switzerland) in 362 adult patients with suspected infections and evaluated their qSOFA and NEWS2 scores. Objectives included evaluating qSOFA's performance, assessing the performance of PSP to identify high-risk patients with qSOFA ≤1, and determining the added value of combining PSP with qSOFA or NEWS2 (cutoff ≥7), using standard performance metrics.
resultsAmong 156 sepsis cases, 128 (82.1%) had qSOFA scores ≤1. A qSOFA score ≥2 demonstrated sensitivity 17.9% and specificity 97.1% for sepsis diagnosis. In comparison, a qSOFA score of 1 showed a sensitivity of 44.2% and a specificity of 63.6%, while a score of 0 yielded a sensitivity of 37.8% and a specificity of 39.3%. The addition of PSP (cutoff: 300 ng/mL) to qSOFA ≤1 improved specificity to 94.0%, with a sensitivity of 14.8%-closely mirroring the performance of qSOFA ≥2. Similarly, combining PSP with NEWS2 <7 increased true positive cases from 34 to 52, enhancing sensitivity while maintaining high specificity.
conclusionsThis study highlights the utility of combining PSP levels in the patient's blood with existing scoring systems to enhance early sepsis detection in high-risk ED patients. Future research will explore near-patient PSP measurements at ED triage to further refine and expedite sepsis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.